Table 1.
Training cohort (n = 176) | P | Validation cohort (n = 88) | P | |||
---|---|---|---|---|---|---|
HC | GC | HC | GC | |||
(n = 88) | (n = 88) | (n = 44) | (n = 44) | |||
Age (years) | ||||||
Median (range) | 68 (38–83) | 69 (42–85) | 0.550a | 68 (40–88) | 68 (45–77) | 0.960a |
Sex | ||||||
Male | 67 | 63 | 0.493b | 34 | 36 | 0.597b |
Female | 21 | 25 | 10 | 8 | ||
Serum Cr (mg/dl) | ||||||
Mean ± SD | 0.82 ± 0.17 | 0.81 ± 0.22 | 0.669b | 0.79 ± 0.13 | 0.86 ± 0.30 | 0.154c |
H. pylori | ||||||
Positive | 11 | 39 | <0.001b | 5 | 25 | <0.001b |
Negative | 77 | (46) | (39) | (18) | ||
(Eradicated) | (−30) | (−12) | (−17) | (−2) | ||
(Never infected) | (−47) | (−34) | (−22) | (−16) | ||
Unknown | 0 | 3 | 0 | 1 | ||
Histology | ||||||
Intestinal type | 57 (64.8%) | 31 (70.5%) | ||||
Diffuse type | 31 (35.2%) | 13 (29.5%) | ||||
Stage, n | ||||||
I | 54 (61.4%) | 30 (68.2%) | ||||
II | 10 (11.4%) | 3 (3.4%) | ||||
III | 8 (9.1%) | 4 (9.1%) | ||||
IV | 16 (18.2%) | 7 (15.9%) |
H. pylori-negative includes individuals who have undergone successful eradication. Clinical stage is according to the 7th edition of the UICC-TNM classification.
GC gastric cancer, HC healthy control, n number, Cr creatinine.
aMann–Whitney U test.
bχ2 test.
ct-test.